Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT06220136

Comparison of the Performances of the cTOFR and the mTOFR During Reversal of Deep Neuromuscular Blockade With Sugammadex

Conditions: Neuromuscular Blockade, Anesthesia, General

Sex: All
Ages: 18 Years – 65 Years
Healthy volunteers: No
Enrollment: 200
Sponsor: Ankara University

Location: Ankara University Ankara Altındağ

Summary

It is known that deep neuromuscular block improves surgical conditions, especially during laparoscopic abdominal surgery. Based on this, in the Perioperative Neuromuscular Blockade Management guide published by the ESAIC association in 2022, it is recommended to deepen the level of neuromuscular blockade in cases where surgical conditions need to be improved. Sugammadex should be used to quickly and reliably reverse deep neuromuscular blockade. TOFScan, a 3-dimensional acceleromyograph for neuromuscular monitoring, has become widely used in recent years. With this monitor, it has been shown that in addition to the classical train-of-four ratio (cTOFR), the modified train-of-four ratio (mTOFR) can be used during the spontaneous recovery of nondepolarizing neuromuscular blockade. In a study conducted by Schmartz et al. in 2021, it was shown that mTOFR, which is the ratio of T4 to the reference stimulus, was compiled later than cTOFR. Therefore, it is suggested that the mTOFR value is a better determinant for safe extubation.

Eligibility Criteria

Inclusion Criteria: * Age: 18 - 65 (not including 65) * BMI: 18.5-24.9 Exclusion Criteria: * Liver and kidney disease * Non-consenting * Emergency surgeries * Muscle disease * Allergy to rocuronium and sugammadex * Patients predicted to have difficult mask ventilation or difficult intubation * Pregnant and breastfeeding women

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06220136). StuddyBuddy aggregates publicly available trial information.